This company seems to have been delisted
Reason: Acquired by Carlyle and SK Capital
Source: https://www.fiercepharma.com/pharma/once-valued-10b-bluebird-bio-sells-private-equity-firms-29m
Reason: Acquired by Carlyle and SK Capital
Source: https://www.fiercepharma.com/pharma/once-valued-10b-bluebird-bio-sells-private-equity-firms-29m
bluebird bio
BLUE
NZ$8.15
Share price
0.00%
Change (1 day)
-75.71%
Change (1 year)
bluebird bio (BLUE) - Total assets
Total assets on the balance sheet as of March 2025 : NZ$0.48 Billion
According to bluebird bio 's latest financial reports the company's total assets are NZ$0.48 Billion. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
bluebird bio - Total assets on balance sheet (from 2012 to 2025)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2024-12-31 | NZ$0.81 B | -16.65% |
| 2023-12-31 | NZ$0.97 B | 9.09% |
| 2022-12-31 | NZ$0.89 B | 3.24% |
| 2021-12-31 | NZ$0.86 B | -64.79% |
| 2020-12-31 | NZ$2.46 B | -3.75% |
| 2019-12-31 | NZ$2.56 B | -23.29% |
| 2018-12-31 | NZ$3.34 B | 24.95% |
| 2017-12-31 | NZ$2.67 B | 65.79% |
| 2016-12-31 | NZ$1.61 B | 10.22% |
| 2015-12-31 | NZ$1.46 B | 106.11% |
| 2014-12-31 | NZ$0.71 B | 160.22% |
| 2013-12-31 | NZ$0.27 B | 224.04% |
| 2012-12-31 | NZ$84.26 M | 112.72% |
| 2011-12-31 | NZ$39.61 M |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 BioMarin Pharmaceutical BMRN | NZ$11.71 B | 2,314.88% | 🇺🇸 USA |
 Acceleron Pharma XLRN | N/A | N/A | 🇺🇸 USA |
 Sanofi SNY | NZ$233.87 B | 48,113.76% | 🇫🇷 France |
 Sangamo Therapeutics
SGMO | NZ$0.14 B | -70.89% | 🇺🇸 USA |
 Merck MRK | NZ$188.68 B | 38,798.22% | 🇺🇸 USA |
 GlycoMimetics
GLYC | NZ$9.82 M | -97.98% | 🇺🇸 USA |